Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcare● Active
$13.71
$-0.04(-0.29%)
Market Cap$4.4B
P/E Ratio—
52W High$15.42
52W Low$7.53
Amneal Pharmaceuticals, Inc. (AMRX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMRX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.07B | ($0.07B) | ($0.05B) | ($0.25B) | $0.01B |
| Depreciation & Amort. | $0.22B | $0.24B | $0.23B | $0.24B | $0.23B |
| Stock-Based Comp. | $0.03B | $0.03B | $0.03B | $0.03B | $0.00B |
| Change in Working Capital | ($0.20B) | ($0.00B) | ($0.05B) | ($0.06B) | ($0.13B) |
| Net Cash from Operations | $0.34B | $0.30B | $0.35B | $0.07B | $0.24B |
| Investing Activities | |||||
| Capital Expenditure | ($0.07B) | ($0.07B) | ($0.07B) | ($0.09B) | ($0.05B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.11B) | ($0.06B) | ($0.07B) | ($0.17B) | ($0.19B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.03B | ($0.19B) | $0.02B | ($0.04B) | ($0.08B) |
| Net Cash from Financing | ($0.03B) | ($0.21B) | ($0.21B) | ($0.11B) | ($0.14B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.27B | $0.22B | $0.28B | ($0.03B) | $0.19B |
| FCF Margin %(computed) | 8.94% | 7.88% | 11.55% | -1.15% | 9.27% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Amneal Pharmaceuticals, Inc. data
About Amneal Pharmaceuticals, Inc. (AMRX) Cash Flow Statement
Amneal Pharmaceuticals, Inc. generated operating cash flow of $0.34B and free cash flow of $0.27B for 2025 — a FCF margin of 8.94%. Capital expenditure was ($0.07B).
Frequently asked questions
AMRX · 4 questionsAmneal Pharmaceuticals, Inc. generated free cash flow of $0.27B for 2025, up 22.6% year-over-year.
AMRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10